Citius Pharmaceuticals, Inc. - Common Stock (CTXR)
0.8006
-0.2394 (-23.02%)
NASDAQ · Last Trade: Dec 25th, 3:41 PM EST
Detailed Quote
Previous Close
1.040
Open
1.180
Bid
0.7800
Ask
0.7920
Day's Range
0.6300 - 1.180
52 Week Range
0.6300 - 4.510
Volume
18,729,015
Market Cap
116.87M
PE Ratio (TTM)
-0.2301
EPS (TTM)
-3.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,456,235
Chart
About Citius Pharmaceuticals, Inc. - Common Stock (CTXR)
Citius Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapeutic products for critical care and cancer treatment. The company primarily specializes in the formulation and commercialization of medical products that aim to address unmet medical needs in the areas of oncology and critical care medicine. Citius is actively engaged in advancing its product pipeline through clinical trials, emphasizing the development of safe and effective therapies to improve patient outcomes. The company's commitment to research and development positions it as a key player in the pharmaceutical landscape, aiming to provide new treatment options for healthcare providers and patients alike. Read More
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
CRANFORD, NJ — As the 2025 calendar year draws to a close, Citius Oncology, Inc. (Nasdaq: CTOR) has reached a pivotal juncture in its corporate evolution. Following the release of its SEC 10-K filing for the fiscal year ended September 30, 2025, the company has officially shed its "development-stage" label, entering
After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Cancer rarely moves fast. It simmers. In the case of cutaneous T-cell lymphoma, or CTCL, it creeps beneath the skin for years, sometimes decades, before erupting into a full malignancy. Patients endure chronic pain, itching, and lesions while cycling through therapy after therapy, chasing control rather than cure. The condition is rare, devastating, and underserved. That is what makes the story of Citius Pharmaceuticals (NASDAQ: CTXR) so critical. Because while the disease moves slowly, Citius has not.
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
